Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.

Neurology - 8 Aug 2000

Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K

Abstract excerpt

Plasma homocysteine and cysteine levels were measured in 90 patients with PD with the MTHFR C677T (T/T) genotype. The authors found that the levels of homocysteine-a possible risk factor for vascular disease-were elevated by 60% in levodopa-treated patients with PD, with the most marked elevation occurring in patients with the T/T genotype. Cysteine levels in subjects with PD did not differ from levels in control...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Cysteine
Share to Folic Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Homocysteine

Share to Levodopa

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Oxidoreductases Acting on CH-NH Group Donors

Share to Parkinson Disease

Source

Identifiers

PMID: 10932284
DOI: 10.1212/wnl.55.3.437

Genes

MTHFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.PMID 10932284Read ↗

Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.Semantic proximity Read ↗

Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.Semantic proximity Read ↗

Homocysteine levels, genetic background, and cognitive impairment in Parkinson's disease.Semantic proximity Read ↗

Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapySemantic proximity Read ↗

Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinson's disease: a meta-analysis.Semantic proximity Read ↗

Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.Semantic proximity Read ↗

Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic studySemantic proximity Read ↗

Methylenetetrahydrofolate reductase C677T genotype and PD.Semantic proximity Read ↗

Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.Semantic proximity Read ↗

Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T Polymorphism in Levodopa-treated Parkinson’s Disease PatientsSemantic proximity Read ↗

Association of MTHFR, MTR, and MTRR polymorphisms with Parkinson's disease among ethnic Chinese in Taiwan.Semantic proximity Read ↗

Homocysteine, vitamin B12, serum and erythrocyte folate in peritoneal dialysis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.